Remodulin (R) ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 88 | Chronic thromboembolic pulmonary hypertension | 1 |
88. Chronic thromboembolic pulmonary hypertension
Clinical trials : 159 / Drugs : 118 - (DrugBank : 23) / Drug target genes : 13 - Drug target pathways : 53
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2008-006441-10-SK (EUCTR) | 31/08/2009 | 09/09/2009 | Double Blind Controlled Clinical Investigation into the Efficacy and Tolerability of subcutaneously administered Treprostinil Sodium in Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension | Double Blind Controlled Clinical Investigation into the Efficacy and Tolerability of subcutaneously administered Treprostinil Sodium in Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension | Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension | Trade Name: Remodulin (R) Trade Name: Remodulin (R) | MRN-Medical Research Network GmbH | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 3 | Czech Republic;Slovakia;Austria;Germany |